BioCryst gets BARDA contract to produce new treatment; Mutual recalls drug made for Sun;

> The Biomedical Advanced Research and Development Authority (BARDA) has awarded BioCryst Pharmaceuticals a $35 million contract to develop and manufacture, a potential treatment for diseases caused by RNA pathogens, including filoviruses. Report 

> Mylan ($MYL) is recalling more than 935 vials of DOXOrubicin Hydrochloride Injection, manufactured for it in India by Onco Therapies after a vial of Ifosfamide Injection was found in a pack. Report

> Mutual Pharmaceutical Company is recalling 23,246 bottles of ergoloid mesylates that it manufactured for Sun Pharmaceutical after the drug for dizziness failed long-term impuriies testing. Report

> Greenville, NC-based CDMO Metrics Contract Services has invested $200,000 in equipment that will help clients to meet higher standards of impurities testing. Release

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.